105 filings
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
DEFA14A
CRBU
Caribou Biosciences Inc
25 Apr 24
Additional proxy soliciting materials
4:04pm
DEF 14A
CRBU
Caribou Biosciences Inc
Definitive proxy
25 Apr 24
4:02pm
8-K
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
S-8
CRBU
Caribou Biosciences Inc
11 Mar 24
Registration of securities for employees
5:08pm
8-K
9iont idgsn81g2f0i
11 Mar 24
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:22pm
8-K
5etq 5b41b
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
5q5mcsq uo6zjso
22 Dec 23
Departure of Directors or Certain Officers
4:05pm
8-K
zcnt5 mhp41c
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
pn54r
7 Nov 23
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
w5ztzi9 zjs5prk
18 Oct 23
Regulation FD Disclosure
8:02am
8-K
ldafetnjex6ht
26 Sep 23
Termination of a Material Definitive Agreement
4:05pm
8-K
4d5utbnzjp2pb 2q6vz
8 Aug 23
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
4:03pm
8-K
1iwjzd5 1apemqo9q3
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
5hlqkwb
14 Jul 23
Prospectus supplement for primary offering
5:31pm